03.08.23 -- Enabling And Advancing RNA-LNP From Concept To Clinic

Manufacturing the RNA-containing LNPs is a complex process and demands specialized expertise and experience. Developing a drug is time-consuming, complex, and multifaceted, requiring enormous investment and extensive resources. Explore some of the challenges of RNA-LNP drug manufacturing, along with the advantages of outsourcing RNA-LNP formulations.

mRNA technology is new and still in the early stages, with no standardized manufacturing protocols. One of the biggest challenges is the formulation of mRNA delivery systems such as lipid nanoparticles (LNPs). Learn about evading impurities in lipids, the significance of the 'biological readout,' and the future of mRNA-based genomic medicines.

Fueled by the success of the mRNA-based COVID-19 vaccines, RNA-based medicines are poised to revolutionize the pharmaceutical industry. Each phase of mRNA-based therapeutic development consists of specific goals, steps, and end points. Learn the fundamentals of manufacturing mRNA-lipid nanoparticle (LNP) drug products from discovery to commercialization.

A promising new approach for T-cell engineering is the use of RNA to express therapeutic proteins and gene editing nucleases. Explore optimization strategies for T-cell gene editing, CRISPR/Cas9-mediated knockouts of the T-cell receptor, multistep LNP engineering to produce TCRɑΒ KO CAR T cells, and more.